Congenital Myasthenic Syndrome 18 (CMS18) — Comprehensive Research Report

Important Nomenclature Note (Read First)

Searches for "Congenital Myasthenic Syndrome 18/CMS18" frequently surface material on COL13A1, but that gene causes a different, higher-numbered entity — Congenital Myasthenic Syndrome 19 (CMS19, OMIM #616720) — not CMS18. This is a common confusion because the numbering is easy to mistransc­ribe and because COL13A1-CMS dominates recent CMS literature volume.

CMS18 is the SNAP25-related disorder, OMIM #616330, originally named "Myasthenic syndrome, congenital, 18, with intellectual disability and ataxia" and gene symbol SNAP25 (synaptosome-associated protein 25, 20p12.2). OMIM's clinical synopsis for this entry has since been folded into/relabeled "Developmental and Epileptic Encephalopathy 117" (DEE117) as the phenotypic spectrum of SNAP25 heterozygous variants was found to extend beyond myasthenia into a broader neurodevelopmental/epileptic encephalopathy continuum. MedGen (Concept ID C4225364) still lists "Congenital myasthenic syndrome 18" as a synonym/legacy label for the same OMIM #616330 entity, and the disease is also cataloged under HGNC gene aliases RIC-4, SEC9, SUP, SNAP for the SNAP25 protein. This report treats CMS18 = SNAP25-related presynaptic CMS/DEE (OMIM #616330) throughout, and flags where source material blends into the wider DEE117 phenotype.

1. Disease Information

Overview: CMS18 is a rare, autosomal-dominant presynaptic congenital myasthenic syndrome caused by heterozygous (typically de novo) missense or truncating variants in SNAP25, a core SNARE-complex protein required for calcium-triggered synaptic vesicle exocytosis. Unlike the majority of CMS subtypes — which are autosomal recessive and confined to the neuromuscular junction (NMJ) — CMS18 is dominant and produces a combined phenotype of fatigable myasthenic weakness plus CNS dysfunction (cortical hyperexcitability/epilepsy, cerebellar ataxia, and intellectual disability), reflecting SNAP25's essential role in exocytosis at both the NMJ and central synapses.

Key identifiers: - OMIM #616330 — "Myasthenic syndrome, congenital, 18, with intellectual disability and ataxia" / "Developmental and epileptic encephalopathy 117; DEE117" - OMIM gene entry *600322 — SNAP25 (Synaptosomal-Associated Protein, 25-KD) - MedGen: C4225364 ("Congenital myasthenic syndrome 18") - HGNC: SNAP25, HGNC:11132; cytogenetic location 20p12.2 - NCBI Gene ID: 6616 - Gene aliases: SNAP-25, RIC-4, RIC4, SEC9, SUP - Orphanet: listed under the broader "Congenital myasthenic syndrome" grouping (ORPHA:590); a dedicated presynaptic-CMS/SNAP25 stub is cross-referenced under the mechanistic Orphanet grouping for defective synaptic vesicle cycling - Frequency in the CMS spectrum: <1% of all genetically solved CMS cases — among the rarest presynaptic CMS subtypes (GeneReviews Congenital Myasthenic Syndromes Overview, NBK1168)

Synonyms: CMS18; SNAP25-related congenital myasthenic syndrome; Myasthenic syndrome, congenital 18, with intellectual disability and ataxia; Developmental and epileptic encephalopathy-117 (DEE117); SNAP25 encephalopathy

Data provenance: Knowledge is derived almost entirely from individual published case reports/series (fewer than 10-15 molecularly confirmed patients described to date across the founding 2014 report, subsequent DEE-focused cohorts, and isolated case reports) plus mechanistic biophysical/cell-biology studies of the specific mutant alleles — not from large aggregated disease registries. This is characteristic of an ultra-rare, recently delineated Mendelian disorder.

2. Etiology

Primary cause: Heterozygous, almost always de novo, missense or nonsense variants in SNAP25, encoding a t-SNARE protein essential for synaptic vesicle docking, priming, and calcium-triggered fusion at both the presynaptic motor nerve terminal and central synapses.

Genetic risk factors / mechanism of pathogenicity: - Dominant-negative mechanism is well established for the founding mutation (I67N): mutant SNAP25B protein incorporates into SNARE complexes and destabilizes/poisons them even in the presence of wild-type protein, rather than simply reducing gene dosage (haploinsufficiency). - SNAP25 is under strong evolutionary and population constraint consistent with the dominant, de novo disease mechanism — gnomAD-type constraint metrics for genes causing severe dominant neurodevelopmental disease from de novo variants typically show high missense and loss-of-function intolerance (elevated missense Z-score / pLI), consistent with SNAP25 being depleted of both truncating and disruptive missense variation in the general population (per general gnomAD constraint methodology; Wilfert et al., gene-constraint/genotype-phenotype correlation studies, PMC10340126). - No recessive/biallelic SNAP25 CMS has been reported — inheritance is monogenic autosomal dominant with each reported case arising as a de novo event in an otherwise unaffected family (no vertical transmission reported to date, consistent with the severity of the phenotype limiting reproductive fitness).

Environmental/other risk factors: None identified — this is a monogenic disorder with no known environmental, infectious, or lifestyle contribution to disease occurrence. No consanguinity signal (dominant de novo mechanism).

Protective factors: None specifically described. No modifier alleles have been reported; phenotypic variability across the small number of known cases appears driven by variant-specific biophysical mechanism (see Section 6) rather than by identified genetic modifiers.

Gene-environment interactions: Not applicable/not described — no evidence of environmental triggers modifying expressivity has been reported in the literature.

3. Phenotypes

CMS18/SNAP25-CMS phenotypes span neuromuscular (myasthenic), central neurological (epileptic encephalopathy, ataxia), and neurodevelopmental domains, distinguishing it from isolated CMS subtypes.

Core neuromuscular (myasthenic) phenotypes

Central/CNS phenotypes

Phenotype characteristics

• Age of onset: Ranges from prenatal/neonatal (severe cases — decreased fetal movement, arthrogryposis, birth respiratory failure) to infancy/early childhood (typical presenting age for the myasthenia-ataxia-ID triad) to later childhood-onset seizures (index patient, seizure onset ~age 5).
• Severity: Highly variable — from a lethal neonatal presentation (the Gln177Ter nonsense-variant patient died on day 6 of life from respiratory failure) to a moderate, largely stable phenotype persisting into the third decade (D166Y patient, 23 years old at report).
• Progression: Neurological features (ataxia, ID) are generally static/developmental rather than progressive once established, though epilepsy course is variable (the index patient's seizures were described across a multi-year follow-up with variable anticonvulsant response).
• Frequency among affected individuals: Given the very small number of published cases (literature currently comprises roughly the I67N index case, the Q177Ter neonatal case, and the V48F/D166Y encephalopathy-predominant cases characterized functionally in the 2024 eLife paper, plus additional unpublished/registry cases alluded to in reviews), formal phenotype-frequency percentages analogous to HPO annotation frequencies are not established — most features are reported as present/absent per-case rather than as population frequencies.

Quality-of-life impact: Not formally measured with QOL instruments (no EQ-5D/SF-36/PROMIS data identified); qualitatively, the combination of motor weakness, ataxia, and intellectual disability in surviving patients produces substantial functional impairment (non-ambulation or impaired gait, poor/absent speech, dependence for activities of daily living reported in the more severely affected cases per the DEE117 OMIM synopsis).

4. Genetic/Molecular Information

Causal gene: SNAP25 (Synaptosomal-Associated Protein, 25kDa), OMIM 600322, chromosome 20p12.2, HGNC:11132, NCBI Gene ID 6616. Two alternatively spliced isoforms exist — SNAP25a and SNAP25b* — differing in a short internal segment; SNAP25b is the predominant adult neuronal isoform and is the isoform in which the founding I67N mutation was characterized.

Reported pathogenic variants (heterozygous, all reported as de novo):

Variant type/class: Missense (I67N, V48F, D166Y, G86R) and nonsense/truncating (Q177Ter) — no large structural rearrangements or splice-site variants reported for CMS18/SNAP25-CMS to date.

Allele frequency in population databases: Given the extreme rarity and de novo, severe-phenotype dominant mechanism, these specific pathogenic variants are absent or present only as extremely rare singletons in gnomAD/population databases — consistent with strong negative selection against SNAP25 coding variation in the general population (SNAP25 shows population-level constraint against both loss-of-function and disruptive missense variation, per gnomAD gene-constraint conventions).

Somatic vs. germline origin: All molecularly reported cases are germline, de novo, heterozygous variants (not somatic mosaicism in the parents; though within the patient, the index I67N case's electrophysiology showed non-normally distributed quantal-content values that the authors interpreted as possibly reflecting somatic mosaicism at the neuromuscular junction level — an intriguing but not independently confirmed observation).

Functional consequences by variant (loss-of-function vs. gain-of-function vs. dominant-negative): - I67N — classic dominant-negative: destabilizes the SNARE four-helix bundle via loss of a critical hydrophobic packing interaction (replacing hydrophobic Ile [hydropathy +4.5] with hydrophilic Asn [-3.5]); in reconstituted membrane-fusion assays, mutant SNAP25B blocked calcium-triggered v-SNARE/t-SNARE liposome fusion, and cotransfection of mutant with wild-type in chromaffin cells reduced catecholamine release to 11% of wild-type levels, confirming a poisoning/dominant-negative effect on the assembled complex rather than simple haploinsufficiency. - V48F and D166Y — mechanistically distinct "neomorphic" mutations combining loss-of-function (impaired synaptotagmin-1 interaction, reduced Ca²⁺-stimulated fusion, reduced readily-releasable-pool priming) with gain-of-function features (paradoxically enhanced SNARE-partner binding, increased spontaneous release, lowered energy barrier for fusion, and evasion of complexin-mediated fusion clamping) — as characterized in detailed reconstituted-fusion biophysics (eLife 2024, PMID 38411501). - Q177Ter — C-terminal truncation predicted to disrupt the SNARE motif and membrane-proximal region required for complex assembly/stability; associated with the most severe reported phenotype (neonatal lethality).

Modifier genes: None identified/reported.

Epigenetic information: Not reported for this disorder.

Chromosomal abnormalities: Not applicable — CMS18 arises from single-nucleotide/small coding variants in SNAP25, not from copy-number or structural chromosomal changes. (Note: SNAP25 also lies within a chromosomal region relevant to unrelated 20p microdeletion contexts, but that is mechanistically distinct from the point-mutation CMS18/DEE117 disease model and outside this report's scope.)

Suggested ontology bindings: Gene — hgnc:11132 (SNAP25); Molecular function — GO:0005484 (SNARE binding), GO:0061789 (SNARE complex disassembly, if relevant to disassembly-cycle mechanism), GO:0016081 (synaptic vesicle docking); relevant GO Cellular Component — GO:0031201 (SNARE complex), GO:0042734 (presynaptic membrane), GO:0008021 (synaptic vesicle).

5. Environmental Information

Not applicable — no environmental toxins, occupational exposures, radiation, pollution, lifestyle, or infectious triggers are implicated in CMS18 causation. This is a purely genetic (de novo monogenic) disorder. No gene-environment interaction data exist.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Molecular trigger (upstream): Heterozygous de novo SNAP25 variant produces a structurally altered t-SNARE protein (I67N: destabilized coiled-coil; V48F/D166Y: altered synaptotagmin-1-binding interface; Q177Ter: truncated protein).
2. SNARE complex assembly/stability defect: Mutant SNAP25 protein incorporates into the ternary SNARE complex (with syntaxin-1 and VAMP2/synaptobrevin-2) alongside wild-type SNAP25, producing either (a) a destabilized, dominant-negative complex with an increased energy barrier to membrane fusion (I67N), or (b) an aberrantly hyperstable/miswired complex with disrupted synaptotagmin-1 coupling and dysregulated calcium sensing (V48F, D166Y).
3. Impaired calcium-triggered synaptic vesicle exocytosis: Across all characterized variants, calcium-stimulated, synchronous vesicle fusion is compromised — manifesting as reduced evoked quantal release (reduced miniature endplate potential frequency and quantal content at the NMJ) and, in reconstituted central-synapse systems, altered readily-releasable-pool size, altered spontaneous (miniature) release, and altered fusion kinetics.
4. Presynaptic neuromuscular transmission failure: At the motor endplate, this produces the electrophysiological signature of a presynaptic CMS — reduced quantal release with normal postsynaptic acetylcholine receptor density/distribution and normal synaptic vesicle docking morphology (docked vesicles are present but fail to fuse efficiently) — yielding fatigable muscle weakness, ptosis, and (in severe cases) neonatal respiratory failure and arthrogryposis from reduced fetal muscle activity.
5. Central synaptic transmission failure: The same SNARE-complex defect operating in CNS neurons (cortical, cerebellar) produces network-level dysfunction: cortical hyperexcitability/epileptogenesis (paradoxically, impaired inhibitory/excitatory balance from dysregulated vesicle release can manifest as seizures), cerebellar Purkinje/granule-cell circuit dysfunction (ataxia), and impaired synaptic plasticity/circuit maturation underlying intellectual disability and developmental delay.
6. Downstream systemic consequences: Chronic impaired neuromuscular and CNS synaptic function drives the multisystem phenotype — feeding difficulty, hypotonia, contractures/arthrogryposis (reduced in utero movement), and the neurodevelopmental/epilepsy phenotype.

Which mechanisms are upstream vs. downstream: The single unifying upstream lesion is impaired SNARE-complex-mediated, calcium-triggered vesicle fusion; everything else (myasthenic weakness, ataxia, seizures, ID) is a downstream tissue-specific consequence of this one presynaptic mechanism operating in different neuronal populations (motor nerve terminal vs. cortex vs. cerebellum).

Cell types involved (CL terms): - Motor neuron / neuromuscular junction presynaptic terminal — CL:0000100 (motor neuron) - Cortical excitatory/inhibitory neurons — CL:0000598 (pyramidal neuron), CL:0000617 (GABAergic interneuron, if inhibitory dysfunction contributes to hyperexcitability) - Cerebellar Purkinje cells — CL:0000121 (Purkinje cell) - Skeletal muscle fiber (postsynaptic target, secondarily affected) — CL:0000188/CL:0008002

Biological processes (GO terms): - GO:0016079 — synaptic vesicle exocytosis - GO:0031629 — synaptic vesicle fusion to presynaptic active zone membrane - GO:0007269 — neurotransmitter secretion - GO:0099525 — presynaptic dense core vesicle exocytosis (relevant given SNAP25's dual role in synaptic and dense-core-vesicle release) - GO:0060079 — excitatory postsynaptic potential (downstream circuit effect)

Protein dysfunction: Predominantly dominant-negative destabilization (I67N) or neomorphic gain/loss-of-function combination (V48F, D166Y) rather than simple loss-of-function/haploinsufficiency — an important mechanistic nuance versus most recessive LOF-driven CMS genes.

Biochemical abnormalities: Core defect is in the SNARE (soluble NSF-attachment protein receptor) fusion machinery — SNAP25 is the t-SNARE partner of syntaxin-1 (plasma membrane) and VAMP2/synaptobrevin (vesicle membrane); disease variants disrupt either the coiled-coil zippering of the four-helix SNARE bundle or the calcium-sensor (synaptotagmin-1) coupling interface required to convert calcium influx into fast, synchronous fusion.

Molecular/omics profiling: No transcriptomic, proteomic, or metabolomic disease-tissue profiling has been published for human CMS18 patients (tissue inaccessibility in a rare pediatric neuromuscular/CNS disorder); mechanistic insight instead comes from reconstituted biochemical fusion assays (liposome fusion, single-vesicle content-mixing assays), chromaffin-cell exocytosis assays, and electrophysiological recordings from patient intercostal-muscle endplates (microelectrode studies).

Advanced technologies: No single-cell, spatial transcriptomic, or CRISPR screen data specific to human CMS18 tissue have been published. Functional dissection has instead relied on classic single-molecule/reconstitution biophysics (eLife 2024 study) and expression-system electrophysiology (PC12/chromaffin cells, cultured neurons).

7. Anatomical Structures Affected

Organ level: - Primary: Peripheral nervous system — the neuromuscular junction (motor nerve terminal) and skeletal muscle (secondarily, via impaired innervation); central nervous system — cerebral cortex (epileptogenesis), cerebellum (ataxia). - Secondary: Respiratory system (via bulbar/respiratory muscle weakness — the most life-threatening secondary organ involvement, causing neonatal respiratory failure in the severe case); musculoskeletal system (contractures/arthrogryposis, clubfeet from reduced fetal movement); orofacial structures (cleft palate, micrognathia reported in the severe neonatal case, likely also secondary to reduced fetal orofacial muscle activity/deformation). - Body systems involved: Neuromuscular, nervous (central and peripheral), musculoskeletal, and (secondarily, in severe neonatal cases) respiratory.

Tissue and cell level: - Presynaptic nerve terminal (motor and central neurons) — UBERON:0000102 (motor neuron / axon terminal, general presynaptic terminal concept) - Skeletal muscle motor endplate — UBERON:0031594 (neuromuscular junction) if using an anatomical descriptor - Cerebral cortex — UBERON:0000956 - Cerebellum — UBERON:0002037 - Cell populations: motor neurons, cortical pyramidal/interneurons, cerebellar Purkinje and granule cells (see CL terms above)

Subcellular level: - Synaptic vesicle membrane — GO:0008021 (synaptic vesicle) - Presynaptic plasma membrane — GO:0042734 - SNARE complex assembly — GO:0031201 (SNARE complex)

Localization: - Site of primary pathology: presynaptic nerve terminal at both the neuromuscular junction and central synapses (UBERON:0031594 NMJ; cortex/cerebellum for CNS involvement). - Lateralization: Not applicable/no lateralized pattern reported — disease is a diffuse/generalized presynaptic transmission defect (bilateral ptosis, generalized weakness, diffuse cortical/cerebellar dysfunction), not a focal or unilateral process.

8. Temporal Development

Onset: - Typical age of onset: Congenital/neonatal to early childhood. The most severe reported case (Q177Ter) presented prenatally (polyhydramnios, decreased fetal movement) with birth at 35 weeks and immediate respiratory failure. The founding index case (I67N) had an earlier developmental/myasthenic presentation with seizure onset around age 5. The V48F and D166Y cases were characterized as adolescent/young-adult at time of report (15 and 23 years old respectively) with seizure onset in infancy (5 months) for V48F. - Onset pattern: Predominantly congenital/insidious for the myasthenic/hypotonic component (present from birth), with acute-onset possible for the most severe respiratory presentations, and a more subacute/progressive unmasking of the epileptic-encephalopathy component over the first years of life.

Progression: - Disease stages: Not formally staged (no consensus staging system exists for this ultra-rare disorder). - Progression rate/course pattern: Variable and not uniformly progressive — the neurodevelopmental/ataxic component appears largely static once established (a developmental disorder rather than a neurodegenerative one), while epilepsy course fluctuates (index patient's seizures were treatment-resistant for a period, then apparently better controlled). The disease course is best described as "static-to-fluctuating" rather than classically progressive or classically episodic. - Disease duration: Chronic, lifelong in survivors; the most severely affected neonatal patient died on day 6 of life (respiratory failure) — indicating the phenotype spans from neonatal-lethal to a chronic, non-degenerative lifelong neurodevelopmental/myasthenic disorder.

Patterns: - Remission: No spontaneous remission reported; myasthenic component may show partial pharmacologic improvement (index case: neostigmine partially reduced EMG decrement). - Critical periods: The perinatal/neonatal period represents the highest-risk critical window (respiratory failure risk in severe truncating variants); early childhood is the critical window for seizure onset and developmental-trajectory determination.

9. Inheritance and Population

Epidemiology: - Prevalence/incidence: Not formally estimated — CMS18/SNAP25-CMS is one of the rarest genetically defined CMS subtypes, representing <1% of all molecularly solved CMS cases (GeneReviews CMS Overview, NBK1168). Given that CMS overall has an estimated prevalence on the order of 1-9 per 1,000,000 (typical Orphanet-class range for the broader CMS group), SNAP25-CMS/CMS18 itself is almost certainly in the ultra-rare (<1 in 1,000,000) Orphanet prevalence band, with the world literature comprising a handful of published, molecularly confirmed cases.

Inheritance pattern: - Autosomal dominant (AD) — a notable exception among CMS genes, most of which are autosomal recessive. All reported cases have arisen as de novo heterozygous variants (suggested HP inheritance term: HP:0000006 Autosomal dominant, or more specifically HP:0025352 De novo — should be modeled with an Inheritance block bound to the relevant HPO mode-of-inheritance term, HP:0000006, with description noting the de novo pattern per case).

Penetrance: Presumed complete/high given that every reported carrier of a pathogenic SNAP25 variant manifests disease (consistent with the severe, dominant-negative/gain-of-function mechanism), though the very small case number precludes a formal penetrance estimate.

Expressivity: Highly variable — ranging from a mild-to-moderate ataxia/ID/epilepsy phenotype with long-term survival (D166Y, V48F, I67N cases) to a lethal neonatal arthrogrypotic/respiratory-failure phenotype (Q177Ter). This variability appears to track with the specific biophysical mechanism of each variant (dominant-negative destabilization vs. neomorphic gain/loss-of-function vs. truncation) rather than with any identified modifier.

Genetic anticipation: Not applicable/not reported (not a repeat-expansion disorder).

Germline mosaicism: Not formally documented in unaffected parents of reported cases (all cases described as apparently de novo with unaffected, non-mosaic-tested or presumed non-carrier parents); the index I67N patient's own quantal-release data showed a statistical pattern the authors speculated might reflect somatic mosaicism within the patient at the neuromuscular junction, though this remains an unconfirmed hypothesis specific to that case rather than a general germline-mosaicism finding.

Founder effects: None reported — each case has a distinct, apparently independently arising variant.

Consanguinity: Not relevant — dominant de novo mechanism, consistent with reported cases arising in non-consanguineous families (explicitly noted for the neonatal Q177Ter case).

Carrier frequency: Not applicable (not a recessive carrier-screening-relevant disorder; each case is an independent de novo dominant event, not inherited from a carrier parent).

Population demographics: No specific ethnic, geographic, or sex-ratio pattern has been established given the very small number of published cases (a mix of male and female patients reported: the index case was female, the neonatal lethal case was male). No geographic clustering reported.

10. Diagnostics

Clinical tests: - Electrophysiology (key diagnostic modality for presynaptic CMS): Repetitive nerve stimulation showing a decremental response; in vitro microelectrode studies of intercostal-muscle endplates in the index case demonstrated reduced miniature endplate potential (MEPP) frequency (31% of normal) and reduced quantal release probability (63% of normal) with preserved acetylcholine receptor density — the classic presynaptic quantal-release-defect signature distinguishing this CMS category from postsynaptic (e.g., AChR-deficiency) or synaptic-basal-lamina (e.g., COL13A1, COLQ) CMS subtypes. - EMG: Partial reduction of decrement with neostigmine reported in the index case, consistent with a component of neuromuscular junction dysfunction responsive to acetylcholinesterase inhibition, though the primary defect (presynaptic release) is not fully correctable by AChE inhibition. - EEG: Generalized polyspike-wave discharges documented in the index/seizure-affected cases; essential for characterizing the epileptic-encephalopathy component. - Brain MRI: Findings variably include mild diffuse cortical atrophy (D166Y case) and delayed myelination (V48F case); MRI can also be normal. - Muscle biopsy/ultrastructure: Electron microscopy in the index case showed abundant synaptic vesicles normally docked at active zones (i.e., a functional fusion defect, not a structural/vesicle-number defect — vesicles dock but fail to fuse efficiently), an important diagnostic/mechanistic distinguishing feature.

Genetic testing: - Recommended approach: Given the CMS phenotype-gene heterogeneity (>30 genes implicated in CMS) plus the possibility of a broader DEE, CMS gene-panel or exome/genome sequencing is the recommended diagnostic strategy rather than single-gene testing, given SNAP25's atypical (dominant, de novo, CNS-plus-NMJ) presentation that might not immediately suggest "classic CMS" to a clinician expecting recessive, NMJ-limited disease. - Rapid genome sequencing (rWGS): Explicitly demonstrated as diagnostically decisive in the critically ill neonatal case — a 7-day-turnaround rWGS identified the de novo SNAP25 c.529C>T (p.Gln177Ter) variant, illustrating the clinical utility of rapid sequencing in acutely ill neonates with an undifferentiated arthrogryposis/respiratory-failure presentation. - Single-gene testing: Available via clinical laboratories (e.g., NIH GTR lists dedicated SNAP25 sequence-analysis clinical tests for "Myasthenic syndrome, congenital, 18" — GTR test ID 581717) once the phenotype is suspected. - Chromosomal microarray/karyotype/FISH: Not primarily indicated (disease is due to point mutation, not structural rearrangement), though may be part of a standard undiagnosed-arthrogryposis or DEE diagnostic workup to exclude other etiologies. - Variant classification: Reported variants are classified pathogenic per functional/segregation evidence (de novo occurrence, absence from population databases, concordant electrophysiological/biochemical functional data) — consistent with ACMG/AMP criteria PS2 (de novo), PM2 (absent from population databases), PS3 (functional studies), and (for I67N) PM1/PM5-type structural-domain evidence.

Omics-based diagnostics: Not part of routine diagnostic workup; RNA-seq, proteomics, metabolomics not used clinically for this disorder.

Clinical criteria: No formal consensus diagnostic-criteria document specific to SNAP25-CMS exists; diagnosis rests on the combination of (1) fatigable myasthenic weakness with presynaptic electrophysiology, (2) epilepsy/cortical hyperexcitability, (3) ataxia, and (4) intellectual disability/developmental delay, confirmed by molecular identification of a heterozygous de novo pathogenic SNAP25 variant.

Differential diagnosis: Other presynaptic CMS genes (CHAT, SYT2, MUNC13-1/UNC13A, SLC5A7/choline transporter, VAMP1); other genetic causes of developmental and epileptic encephalopathy with ataxia (e.g., STXBP1-DEE, given STXBP1's mechanistic overlap as another SNARE-machinery regulator); other arthrogryposis-associated neuromuscular disorders in the severe neonatal presentation.

Screening: No population newborn-screening or carrier-screening program exists (ultra-rare, de novo dominant disorder not amenable to carrier screening); prenatal diagnosis could theoretically be offered in a family with a previously affected child (recurrence risk driven primarily by the low background rate of germline mosaicism rather than standard Mendelian recurrence risk, though this has not been specifically quantified for SNAP25).

11. Outcome/Prognosis

Survival and mortality: Highly variant-dependent. The Q177Ter truncating variant was associated with neonatal death on day 6 of life from respiratory failure following compassionate extubation. In contrast, patients with the I67N, V48F, and D166Y missense variants have survived into the second and third decades of life (ages 11, 15, and 23 years reported, respectively), indicating that survival is not uniformly poor and depends heavily on the specific variant's severity and the degree of respiratory/bulbar involvement.

Morbidity and function: Surviving patients experience chronic, non-fatal but substantial morbidity — non-fatigable ptosis in adulthood, ataxic gait (sometimes limited by contractures), dysarthria, and intellectual disability ranging from mild to severe with poor or absent speech in more affected individuals. No formal disability-outcome or QOL instrument data available.

Disease course/complications: Chronic contractures (knee flexion), recurrent/treatment-resistant seizures in a subset, and (in the index case) gradual improvement of muscle strength over time is notably not the typical CMS pattern reported for SNAP25 — data here are limited to case-level narrative rather than systematic follow-up. (Contrast: the COL13A1/CMS19 literature, not CMS18, specifically documents strength improvement into adulthood — care should be taken not to conflate the two entities' natural histories.)

Prognostic factors: The clearest identified prognostic determinant in the literature is variant-specific mechanism/severity — truncating/null-like variants (Q177Ter) associated with the most severe, neonatal-lethal phenotype; missense dominant-negative or neomorphic variants (I67N, V48F, D166Y) associated with survival and a chronic but non-degenerative course. No molecular biomarker-based prognostic model exists.

12. Treatment

Pharmacotherapy: - Acetylcholinesterase inhibitors (e.g., pyridostigmine, neostigmine): Standard first-line CMS therapy; in the index (I67N) patient, neostigmine partially reduced the EMG decremental response, indicating some benefit, though — as is typical for presynaptic CMS where the primary defect is release probability rather than receptor availability — benefit is expected to be partial rather than curative. - 3,4-Diaminopyridine (3,4-DAP): A potassium-channel blocker that increases acetylcholine release and prolongs the presynaptic action potential; a rational adjunct for presynaptic CMS given the mechanism, though no published data specifically document 3,4-DAP use/response in a SNAP25-CMS/CMS18 patient in the sources reviewed. General CMS caution: fast-channel CMS patients have died when started on 3,4-DAP, underscoring the need for cautious, monitored introduction of this class in any CMS subtype, including this one, until subtype-specific safety data exist. - Salbutamol (albuterol)/beta-2 agonists: Used in other presynaptic/synaptic-basal-lamina CMS subtypes (e.g., COLQ, COL13A1/CMS19) to improve NMJ structure/function; no SNAP25/CMS18-specific outcome data identified in the reviewed literature — response is undocumented for this specific gene. - No pharmacogenomic (PharmGKB/CPIC) guidance specific to SNAP25-CMS drug selection has been published.

Advanced therapeutics: No gene therapy, cell therapy, RNA-based therapy (ASO/siRNA/mRNA), targeted small-molecule, or immunotherapy approach has been developed or trialed for SNAP25-CMS. Given the dominant-negative/neomorphic mechanism (not simple loss-of-function), an allele-selective knockdown strategy (e.g., ASO) would be a mechanistically rational future direction (analogous to other dominant-negative SNARE/channel disorders) but has not been reported.

Surgical/interventional: No disease-specific surgical intervention reported; general supportive orthopedic management of contractures (e.g., serial casting/tenotomy for arthrogryposis-related contractures) may apply per general arthrogryposis management principles, though not specifically documented for a SNAP25-CMS case.

Supportive/rehabilitative care: - Respiratory support (mechanical ventilation) is critical in severe neonatal presentations and was central to the (unsuccessful) management of the Q177Ter case. - Physical therapy, occupational therapy for contracture management and motor/ataxia-related functional impairment. - Antiepileptic drug management for the seizure component — the index patient's seizures were noted as poorly responsive to valproic acid between ages 5-8, indicating this population may include drug-resistant epilepsy requiring individualized anticonvulsant selection (general DEE-management principles would apply — e.g., broader-spectrum agents, possible ketogenic diet consideration — though no SNAP25-specific antiepileptic-response data were identified). - Speech/communication therapy for patients with absent/impaired speech.

Experimental treatments: No registered clinical trials (ClinicalTrials.gov) specific to SNAP25-CMS/CMS18 were identified in this research.

Treatment outcomes/response rates: No systematic response-rate data exist given the case-report-level evidence base; anecdotal partial response to neostigmine in one patient is the only quantified pharmacologic response documented in the reviewed literature.

Treatment strategy/algorithm: No SNAP25-CMS-specific treatment algorithm exists; management follows general presynaptic-CMS principles (trial of AChE inhibitor ± 3,4-DAP, with caution regarding drugs known to worsen NMJ transmission — see below) combined with standard DEE/epilepsy management and multidisciplinary supportive care (respiratory, orthopedic, developmental).

Drugs to avoid in CMS generally (applies to CMS18 by extension): Ciprofloxacin, chloroquine, procaine/local anesthetics of that class, lithium, phenytoin, beta-blockers, procainamide, and quinidine are flagged in GeneReviews as agents that can exacerbate neuromuscular transmission defects across CMS subtypes and should be used cautiously if at all.

NCIT term suggestions: Pharmacotherapy (NCIT:C15986); the specific AChE-inhibitor and 3,4-DAP mechanisms would be captured via therapeutic_agent (CHEBI terms for pyridostigmine, neostigmine, amifampridine/3,4-DAP, salbutamol) rather than a distinct NCIT action term beyond generic pharmacotherapy.

13. Prevention

Primary prevention: Not applicable — as a de novo dominant disorder with no identified environmental trigger, there is no primary-prevention strategy (no vaccination, risk-factor modification, or avoidable exposure relevant to causation).

Secondary prevention/screening: No population or targeted screening program exists. Prenatal diagnosis (via chorionic villus sampling/amniocentesis with targeted variant testing) could be offered in the rare scenario of a family with a previously molecularly confirmed affected child, given the small but nonzero possibility of parental germline mosaicism, though this has not been formally quantified for SNAP25.

Genetic counseling: Recurrence risk for future pregnancies in a family with one affected child is expected to be low but not zero (consistent with de novo dominant disorders generally, accounting for the possibility, though unconfirmed for SNAP25, of low-level parental germline mosaicism); genetic counseling should convey this general de novo-dominant recurrence framework (typically quoted in the 1-2% range for de novo dominant conditions generically, pending disorder-specific data) rather than the ~25%/50% Mendelian recurrence risks that apply to recessive/dominant-inherited CMS subtypes.

Public health/behavioral interventions: Not applicable — no modifiable behavioral, dietary, or environmental risk factor has been identified for this monogenic disorder.

Prophylaxis: Not applicable.

14. Other Species / Natural Disease

Taxonomy: No naturally occurring SNAP25-related myasthenic/encephalopathic disease has been reported in non-human species (companion animals, livestock, or wildlife) in the literature reviewed. SNAP25 orthologs are highly conserved across vertebrates (human SNAP25 gene ID 6616; mouse ortholog Snap25, MGI:98331; conservation extends to Drosophila and yeast, as reflected in the cross-species functional-domain conservation discussed below).

Natural disease/veterinary relevance: Not documented — no OMIA (Online Mendelian Inheritance in Animals) entries or veterinary case series for spontaneous SNAP25-associated disease were identified.

Comparative biology/evolutionary conservation: The SNARE-complex fusion mechanism disrupted in CMS18 is deeply evolutionarily conserved — the yeast SNAP25 homolog SEC9 shows an analogous temperature-sensitivity phenotype when an equivalent coiled-coil domain mutation is introduced, and Drosophila SNAP-25 mutants (SNAP-25ts, Gly50→Glu in the first amphipathic helix) similarly destabilize SNARE complex thermal stability and produce temperature-dependent neurotransmission defects — directly supporting the human dominant-negative destabilization mechanism proposed for I67N.

Transmission: Not applicable — non-communicable monogenic disorder, no zoonotic or cross-species transmission relevance.

15. Model Organisms

Mouse models: - Snap25 null (knockout) mice: Homozygous null is embryonic/perinatal lethal — Snap25⁻/⁻ mice die at birth due to failure of evoked (calcium-triggered) neurotransmitter release, while spontaneous release persists, directly demonstrating SNAP25's essential, non-redundant role in fast synchronous synaptic vesicle exocytosis (the same biochemical process disrupted by the human dominant-negative/neomorphic disease variants). Heterozygous Snap25⁺/⁻ mice survive to adulthood and are fertile, showing relatively mild behavioral phenotypes (notably hypoactivity) — a haploinsufficiency model that is mechanistically distinct from (and phenotypically milder than) the human dominant-negative disease alleles, illustrating that the human disease variants are not simple loss-of-function/dosage models. - "Blind-drunk" mouse (Snap25 I67T, or per some literature descriptions "S187A"-adjacent regulatory-domain models): A dominant, spontaneous Snap25 point mutation (I67T — note the striking similarity to the human I67N disease variant, affecting the identical residue) causes impaired vesicle trafficking, abnormal sensorimotor gating, and ataxia in heterozygous mice — a close phenotypic and molecular parallel to human CMS18/DEE117, providing strong cross-species validation that mutation at this specific SNAP25 residue produces a dominant, SNARE-destabilizing, ataxia-associated phenotype. This model has additionally been used to study impaired pancreatic beta-cell granule exocytosis and psychiatric/schizophrenia-relevant endophenotypes (impaired sensorimotor gating), reflecting SNAP25's broader dense-core-vesicle exocytosis role beyond classical fast synaptic transmission. - Region/cell-type-specific conditional Snap25 deletion models (e.g., cortical-projection-neuron-specific loss) have been used to dissect circuit-specific consequences relevant to the cortical hyperexcitability/epilepsy component of the human phenotype, and brain-specific SNAP-25 deletion models show elevated extracellular glutamate and schizophrenia-like behavior, offering a partial model for the CNS excitability phenotype.

Invertebrate models: - Drosophila SNAP-25ts (temperature-sensitive paralytic mutant, Gly50→Glu): demonstrates that SNARE complex assembly/disassembly cycling is required for synaptic exocytosis; the mutant SNARE complex is thermally unstable at 37°C (dissociates), producing temperature-dependent facilitation (increased release at permissive temperature) followed by failure of release (restrictive temperature) — mechanistically informative for understanding how discrete point mutations destabilize the SNARE bundle, directly analogous to the human I67N dominant-negative mechanism. - Yeast SEC9 (SNAP25 homolog): an equivalent coiled-coil domain mutation confers temperature sensitivity, underscoring deep conservation of this structural mechanism across ~1 billion years of eukaryotic evolution.

Cellular/in vitro models: - PC12/chromaffin cell transfection systems: Used to directly test human disease-variant SNAP25 constructs for dominant-negative effects on catecholamine (dense-core vesicle) release — the I67N mutant reduced release to 11% of wild-type when cotransfected with wild-type protein, the key functional evidence establishing dominant-negative pathogenicity for this variant in a human-relevant expression system. - Reconstituted liposome/membrane-fusion assays and single-vesicle content-mixing assays: Used extensively (Shen et al. 2014; the 2024 eLife biophysics study) to directly measure the effect of purified mutant SNAP25 protein on calcium-triggered SNARE-mediated membrane fusion kinetics, priming, and the energy landscape of vesicle fusion — the most mechanistically granular data source available for this disease, distinguishing the dominant-negative (I67N) mechanism from the neomorphic gain/loss-of-function (V48F, D166Y) mechanism at a biophysical level. - Cultured neuron electrophysiology (mEPSC/EPSC recordings): Used to characterize the V48F, D166Y, and I67N variants' distinct effects on spontaneous miniature release frequency, evoked EPSC amplitude, and readily-releasable-pool size in central-synapse-relevant neuronal culture systems.

Model recapitulation/limitations: The mouse and Drosophila models recapitulate the core presynaptic exocytosis defect and, in the case of the blind-drunk I67T mouse, the ataxia/sensorimotor phenotype with notable fidelity to the analogous human I67N variant. However, no existing animal model fully recapitulates the combined myasthenic + epileptic-encephalopathy + intellectual-disability phenotype seen in human CMS18 patients within a single system, and the complete embryonic/perinatal lethality of the full null mouse model limits its use for studying postnatal disease progression — heterozygous point-mutant "knock-in" models (blind-drunk I67T; other knock-in efforts referenced in the literature) are therefore the most translationally relevant available resource, though systematic characterization of NMJ-specific (as opposed to CNS) phenotypes in these models is not comprehensively reported in the sources reviewed.

Summary of Key Evidence Citations

Sources: - Entry - #616330 - DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 117; DEE117 - OMIM - Entry - *600322 - SYNAPTOSOMAL-ASSOCIATED PROTEIN, 25-KD; SNAP25 - OMIM - Congenital myasthenic syndrome 18 - NIH Genetic Testing Registry (GTR) - Congenital myasthenic syndrome 18 (Concept Id: C4225364) - MedGen - Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability - PMC (PMID 25381298) - Rapid genome sequencing identifies a novel de novo SNAP25 variant for neonatal congenital myasthenic syndrome - PMC - SNAP25 disease mutations change the energy landscape for synaptic exocytosis due to aberrant SNARE interactions - eLife (PMID 38411501) - Congenital Myasthenic Syndromes Overview - GeneReviews (NBK1168) - A dominant mutation in Snap25 causes impaired vesicle trafficking, sensorimotor gating, and ataxia in the blind-drunk mouse - PNAS (PMID 17283335) - Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1 - PMC (for CMS18/CMS19 disambiguation) - SNAP25 gene - GeneCards - NM_130811.4(SNAP25):c.256G>A (p.Gly86Arg) AND Congenital myasthenic syndrome 18 - ClinVar - Two distinct effects on neurotransmission in a temperature-sensitive SNAP-25 mutant - PubMed - Temperature-Sensitive Paralytic Mutations Demonstrate that Synaptic Exocytosis Requires SNARE Complex Assembly and Disassembly - Neuron (PMID 9728921)

Congenital Myasthenic Syndrome 18 (CMS18): A Comprehensive Disease Characteristics Report

Disease: Congenital Myasthenic Syndrome 18 (CMS18) MONDO ID: MONDO:0014590 · OMIM: #616330 · Causal gene: SNAP25 (HGNC:11132; NCBI Gene 6616) Category: Mendelian (autosomal dominant, de novo)

Summary

Congenital Myasthenic Syndrome 18 (CMS18) is an ultra-rare, autosomal-dominant, presynaptic congenital myasthenic syndrome caused by a de novo missense variant (p.Ile67Asn) in SNAP25, the gene encoding the t-SNARE protein SNAP-25 (synaptosomal-associated protein of 25 kDa). SNAP-25 is one of three core SNARE proteins that drive calcium-triggered fusion of synaptic vesicles at the nerve terminal. The pathogenic variant disrupts SNARE-complex assembly and Ca²⁺-triggered exocytosis, reducing quantal acetylcholine release and thereby lowering the safety margin of neuromuscular transmission. The clinical result is fatigable myasthenic muscle weakness combined with prominent central nervous system features — cortical hyperexcitability/epilepsy, cerebellar ataxia, and intellectual disability — because SNAP-25 is essential for both neuromuscular and central synaptic transmission (PMID: 25381298).

CMS18 sits at the intersection of two disease concepts. It is formally a congenital myasthenic syndrome (the 18th numbered subtype), but it also belongs to the broader SNAP25 developmental and epileptic encephalopathy (SNAP25-DEE) spectrum — part of a family of neurodevelopmental disorders now termed "SNAREopathies" that also encompass STX1B, STXBP1, and VAMP2 (PMID: 33299146). The myasthenic phenotype is the distinguishing feature of the original CMS18 patient, whereas most reported SNAP25 patients present chiefly with encephalopathy. This dual identity is central to understanding the disease: the same gene, and even variants clustered in the same structural region, can produce a spectrum from predominantly myasthenic to predominantly encephalopathic phenotypes depending on the precise synaptic consequence of each variant.

Congenital myasthenic syndromes as a group are ultra-rare (UK genetically-confirmed prevalence ≈ 6.5 per million overall; 8.5 per million pediatric), and CMS18 is one of the very rarest subtypes — only a handful of cases worldwide, dwarfed by the common CHRNE, DOK7, and RAPSN subtypes (PMID: 41251564). There is no cure. Management is symptomatic and genotype-guided: because CMS18 is a presynaptic release defect, release-enhancing agents such as 3,4-diaminopyridine (a Kv-channel blocker that prolongs nerve-terminal depolarization) and β-adrenergic agonists are the rational first-line choices, while cholinesterase inhibitors must be used cautiously because they worsen certain CMS subtypes (PMID: 24425145, PMID: 36308527). CNS features additionally require antiseizure and supportive/rehabilitative care.

1. Disease Information

Overview. CMS18 is a genetic disorder of neuromuscular transmission in which the safety margin of the neuromuscular junction (NMJ) is impaired by a presynaptic defect in synaptic vesicle exocytosis. Unlike most CMS subtypes, which affect only the NMJ, CMS18 also affects central synapses, producing a combined neuromuscular-plus-neurodevelopmental phenotype (myasthenia, cortical hyperexcitability, cerebellar ataxia, intellectual disability) (PMID: 25381298).

Key identifiers (verified via EBI OLS4 / Ontology Lookup Service — Finding F006):

Synonyms and alternative names (registered in MONDO): - Myasthenic syndrome, congenital, 18, with intellectual disability and ataxia - CMS18 - SNAP25 congenital myasthenic syndrome - SNAP25-DEE (SNAP25 developmental and epileptic encephalopathy) - Congenital myasthenic syndrome caused by mutation in SNAP25

Source type. The disease-level information here is derived from aggregated disease-level resources (OMIM, MONDO, Orphanet, ontology databases) and from individual patient reports / small case series in the primary literature (the index CMS18 patient in Shen et al. 2014; the ~23-individual SNAP25-DEE cohort in Klöckner et al. 2021). This is not EHR-derived population data — case counts are too small.

2. Etiology

Primary cause — genetic. CMS18 is caused by a dominant de novo missense variant in SNAP25 (canonical index variant: p.Ile67Asn, in the neuronal SNAP25B splice isoform). It is a monogenic Mendelian disorder; the index case arose de novo (not inherited), which is typical of dominant SNARE-complex neurodevelopmental disorders (PMID: 25381298).

"Exome sequencing identified a dominant de novo variant, p.Ile67Asn, in SNAP25B, a SNARE protein essential for exocytosis of synaptic vesicles from nerve terminals and of dense-core vesicles from endocrine cells." — Shen et al. 2014 (PMID: 25381298)

Genetic risk factors. The single causal variant is the disease. There are no known susceptibility loci or common-variant risk factors — this is a fully penetrant monogenic dominant disorder driven by a single de novo change. No modifier genes have been established for CMS18 specifically, although the broader literature suggests the precise variant (and its differential effect on evoked vs spontaneous release) is the main determinant of phenotype severity and character (PMID: 33147442).

Environmental risk factors. None established. As a de novo dominant Mendelian disorder, disease occurrence is not attributable to toxins, lifestyle, occupation, or infection. Advanced parental age is a generic contributor to de novo mutation rates but has not been specifically demonstrated for CMS18.

Protective factors. None identified (genetic or environmental). Not applicable for an ultra-rare monogenic disorder.

Gene–environment interactions. None documented. However, a clinically relevant gene–drug interaction exists: the presynaptic release mechanism of CMS18 dictates that release-enhancing drugs help whereas some cholinesterase inhibitors may not (see §12).

3. Phenotypes

CMS18 combines a peripheral myasthenic phenotype with central nervous system involvement. The index CMS18 patient (Shen 2014) exhibited myasthenia, cortical hyperexcitability, cerebellar ataxia, and intellectual disability; the broader SNAP25-DEE cohort (Klöckner 2021) defines the encephalopathic core.

"Intellectual disability and early-onset epilepsy were identified as the core symptoms of SNAP25-DEE, with recurrent findings of movement disorders, cerebral visual impairment, and brain atrophy." — Klöckner et al. 2021 (PMID: 33299146)

Age of onset. Congenital / early infantile. Seizures in the SNAP25-DEE spectrum typically begin before age 2.

Severity and progression. Variable across the spectrum. Myasthenic weakness is fatigable/fluctuating (characteristic of NMJ disorders); the neurodevelopmental component is largely static-to-slowly-evolving, with epilepsy potentially refractory.

Quality-of-life impact. No disease-specific QoL instrument (EQ-5D, SF-36, PROMIS) data exist for CMS18 given its rarity. By analogy to severe CMS and DEE, the combination of muscle weakness, intellectual disability, and refractory epilepsy imposes substantial impairment on mobility, communication, independent daily functioning, and caregiving burden. This is a qualitative inference, not a measured value.

4. Genetic / Molecular Information

Causal gene. SNAP25 (Synaptosomal-Associated Protein, 25 kDa). HGNC:11132; NCBI Gene 6616; OMIM gene 600322. Located on chromosome 20p11.2. Encodes a t-SNARE (target-membrane SNARE) protein of the plasma membrane. The neuronal splice isoform SNAP25B* is the relevant transcript. Verified gene identifiers (Finding F006 / dossier).

Pathogenic variant. - Nomenclature: p.Ile67Asn (I67N) in SNAP25B protein; a missense substitution replacing isoleucine 67 with asparagine. - Structural location (Finding F002): Ile67 lies within the SN1 (N-terminal) SNARE helix of SNAP-25, the region that participates in the four-helix SNARE bundle. Substituting a hydrophobic Ile with a polar Asn in the coiled-coil interface impairs SNARE-bundle assembly/stability. - Variant class: Missense. - Origin: Germline de novo (present in the affected individual, absent in parents). Not somatic. - Classification: Pathogenic (functionally validated by multiple assays; see §6). - Allele frequency: Absent from population databases (gnomAD) — as expected for a de novo pathogenic variant in an ultra-rare disorder. - Functional consequence: A dominant loss/alteration of function with dominant-negative character — the mutant protein incorporates into SNARE complexes and impairs Ca²⁺-triggered fusion, reducing evoked and spontaneous neurotransmitter release (see Finding F003).

Allelic / phenotypic series. Other SNAP25 de novo variants (missense and loss-of-function) cause SNAP25-DEE without necessarily producing overt myasthenia. Variants cluster structurally but yield related-yet-distinct synaptic phenotypes; e.g., the V48F variant increases spontaneous release, opposite in direction to I67N (PMID: 33147442, PMID: 40181518).

Modifier genes. None established for CMS18. Genetic-background modifiers plausible but undocumented.

Epigenetic information. No disease-specific DNA-methylation or histone-modification data for CMS18. Not applicable / not available.

Chromosomal abnormalities. None — CMS18 is a single-nucleotide missense disorder, not a structural/aneuploidy syndrome.

5. Environmental Information

• Environmental factors: None known to cause or trigger CMS18. Not applicable (monogenic de novo disorder).
• Lifestyle factors: None known. (Generic caution: physical exertion transiently worsens fatigable myasthenic weakness, as in all CMS, but this is symptom modulation, not etiology.)
• Infectious agents: None. CMS18 is not infectious and is not known to be triggered by pathogens. Intercurrent infections/fever can nonspecifically worsen weakness and lower seizure threshold, as in many neurologic disorders, but do not cause the disease.

6. Mechanism / Pathophysiology

Causal chain

De novo SNAP25(B) p.Ile67Asn (SN1 SNARE helix)
│
▼
Impaired assembly / stability of the SNARE 4-helix bundle
 (SNAP-25 + syntaxin-1 + VAMP2/synaptobrevin-2)
│
▼
Defective Ca2+-triggered synaptic-vesicle & dense-core-vesicle fusion
 (reduced evoked AND spontaneous release; decreased release probability)
│
├───────────────► NMJ: reduced quantal ACh release
│                  → lowered safety margin → fatigable weakness (myasthenia)
│
└───────────────► CNS synapses: impaired glutamatergic/GABAergic transmission
           → cortical hyperexcitability/epilepsy, ataxia,
             intellectual disability

Molecular pathway

The core lesion is in SNARE-mediated membrane fusion — the final common step of regulated exocytosis. SNAP-25 is a t-SNARE that, with syntaxin-1 (t-SNARE) and VAMP2/synaptobrevin-2 (v-SNARE), forms the trans-SNARE four-helix bundle that draws vesicle and plasma membranes together for Ca²⁺-triggered fusion (synaptotagmin acts as the Ca²⁺ sensor). GO terms: GO:0006887 (exocytosis), GO:0016079 (synaptic vesicle exocytosis), GO:0017156 (calcium-ion-regulated exocytosis), GO:0031201 (SNARE complex), GO:0099504 (synaptic vesicle cycle).

Direct functional evidence (Findings F001, F003)

Shen et al. 2014 established the causal chain with two independent in-vitro assays plus patient endplate physiology:

"Neuromuscular transmission at patient endplates was compromised by reduced evoked quantal release." — PMID: 25381298

1. Reconstituted fusion: Ca²⁺-triggered liposome fusion was hindered when the t-SNARE carried mutant SNAP25B.
2. Cellular exocytosis: depolarization-evoked exocytosis was markedly reduced in bovine chromaffin cells transfected with mutant SNAP25B.

Østergaard et al. 2025 confirmed the mechanism in a human iPSC-derived NGN2 glutamatergic neuron model engineered to carry I67N:

"the variant did not affect passive or active electrical properties, but caused changes in synaptic transmission, including reduced evoked and spontaneous release, decreased synaptic vesicle release probability and consequential changes in short-term plasticity towards facilitation" — PMID: 40181518

The shift of short-term plasticity toward facilitation is the physiological signature of a reduced initial release probability — exactly what a presynaptic release defect predicts.

Why variants differ (disease heterogeneity)

Alten et al. 2021 showed that structurally clustered SNAP25 mutations produce related but mechanistically distinct phenotypes, with spontaneous release being a key axis of variation:

"specific alterations in spontaneous neurotransmitter release are a key factor to account for disease heterogeneity" — PMID: 33147442

I67N reduces both evoked and spontaneous release, whereas the V48F variant increases spontaneous release — a mechanistic contrast that helps explain why some SNAP25 patients present with prominent myasthenia (release-deficient) while others present with predominantly epileptic encephalopathy.

Cellular / tissue processes

• Cell types (CL terms): motor neuron / cholinergic neuron presynaptic terminals (CL:0000100 motor neuron; CL:0000108 cholinergic neuron), glutamatergic neurons (CL:0000679), GABAergic neurons (CL:0000617), neuroendocrine chromaffin cells (dense-core vesicle release). Skeletal muscle fibers are downstream targets (CL:0000188).
• Subcellular compartments (GO CC): GO:0031201 (SNARE complex), GO:0008021 (synaptic vesicle), GO:0042734 (presynaptic membrane), GO:0030141 (secretory/dense-core granule).
• Protein dysfunction: Not misfolding/aggregation — rather a functional impairment of the SNARE assembly interface with dominant-negative incorporation.
• Immune involvement: None. CMS18 is genetic, not autoimmune — this distinguishes it fundamentally from acquired myasthenia gravis and Lambert-Eaton syndrome. Anti-AChR and anti-MuSK antibodies are negative.
• Metabolic changes: No primary metabolic derangement; the defect is in vesicular exocytosis, not metabolism.

Molecular profiling. Østergaard et al. 2025 additionally reported proteome changes in I67N iPSC neurons alongside the electrophysiologic phenotype (PMID: 40181518); this is the principal omics dataset available for the variant. No transcriptomic, metabolomic, or lipidomic disease signatures specific to CMS18 are established.

7. Anatomical Structures Affected

Organ / system level. - Nervous system (primary): peripheral motor nerve terminals at the NMJ; central synapses (cortex, cerebellum). Body system: nervous + neuromuscular. UBERON: UBERON:0001016 (nervous system), UBERON:0002037 (cerebellum), UBERON:0000956 (cerebral cortex). - Muscular system (target): skeletal muscle, downstream of the failing NMJ. UBERON:0001134 (skeletal muscle tissue); UBERON:0001630 (muscle organ). - Neuromuscular junction (site of primary lesion): UBERON:0002439 (neuromuscular junction) / the presynaptic motor nerve terminal. - Endocrine (subclinical/experimental): dense-core-vesicle secretion (e.g., chromaffin cells) is impaired in vitro; clinical endocrine disease is not a described feature.

Tissue / cell level. Nervous tissue (motor neurons, cortical/cerebellar neurons) and skeletal muscle. Primary cell targets are presynaptic nerve terminals; muscle fibers are secondarily under-stimulated (see CL terms in §6).

Subcellular level. Presynaptic active zone, synaptic vesicle membrane, presynaptic plasma membrane, SNARE complex (GO:0031201).

Localization / lateralization. Generalized and bilateral/symmetric, consistent with a systemic genetic synaptic defect (ptosis, facial, bulbar, limb weakness patterns typical of CMS; central features are diffuse).

8. Temporal Development

• Onset: Congenital / early infantile. Myasthenic features present from birth/infancy; seizures in the spectrum typically before age 2 (PMID: 33299146).
• Onset pattern: Chronic, insidious with fatigable fluctuation of weakness.
• Progression: Chronic and lifelong. The neurodevelopmental component (ID) is largely static; epilepsy may be refractory; myasthenic weakness fluctuates day-to-day and worsens with exertion/fatigue. There is no established staging system.
• Course pattern: Fluctuating/fatigable for the myasthenic component; static-to-slowly-evolving for neurodevelopmental features.
• Duration: Lifelong chronic disorder.
• Remission: No spontaneous remission. Symptomatic pharmacologic improvement is achievable (see §12).
• Critical periods: Early childhood is the key window for seizure control, developmental support, and initiation of NMJ-directed therapy; the developing brain is most vulnerable to uncontrolled epilepsy.

9. Inheritance and Population

Epidemiology. No CMS18-specific prevalence exists (too few cases). The best genetically-confirmed anchor for the CMS umbrella comes from the UK national study (census 31 Dec 2023; 442 patients; Finding F004):

"The UK prevalence was 6.5 cases per million overall and 8.5 cases per million in the pediatric population." — Rossini et al. 2026 (PMID: 41251564)

Prevalence was higher in regions served by highly specialized neuromuscular centers (8.8 vs 5.9 per million), implying underdiagnosis elsewhere. The common subtypes are CHRNE, DOK7, and RAPSN:

"CHRNE deficiency, DOK7, RAPSN were the most common subtypes." — PMID: 41251564

CMS18 (SNAP25) is not among the common subtypes; it is one of the rarest — only a handful of reported cases worldwide, with the entire broader SNAP25-DEE cohort numbering ~23 individuals (PMID: 33299146). A precise CMS18 incidence/prevalence cannot be stated.

Inheritance (genetic etiology). - Pattern: Autosomal dominant, essentially always de novo (index variant arose de novo). - Penetrance: Complete for carriers of the pathogenic de novo variant (each reported carrier is affected). - Expressivity: Variable across the SNAP25 spectrum (myasthenia-predominant vs encephalopathy-predominant), driven largely by the specific variant's synaptic consequence. - Anticipation: Not applicable (not a repeat-expansion disorder). - Germline mosaicism: Theoretically possible for de novo dominant variants (recurrence-risk counseling point) but not documented for CMS18. - Founder effects / consanguinity: Not applicable — de novo dominant, not recessive founder-driven (contrast with recessive CMS subtypes such as certain CHRNE, RAPSN, DOK7 founder alleles). - Carrier frequency: Not applicable (de novo dominant; unaffected "carriers" essentially do not exist).

Population demographics. - Affected populations / geography: No ethnic or geographic clustering — consistent with sporadic de novo occurrence. - Sex ratio: No established sex bias; too few cases. - Age distribution: Onset in infancy/early childhood; patients are predominantly children and young adults.

10. Diagnostics

Clinical / electrophysiologic testing. - Repetitive nerve stimulation (RNS): decrement of the compound muscle action potential on low-frequency (3 Hz) stimulation — abnormal in ~90% of CMS patients (PMID: 33121830). For a presynaptic release defect, features may include low baseline CMAP amplitude with facilitation/increment after exercise or high-frequency stimulation (the presynaptic signature seen in other presynaptic disorders such as LEMS and SYT2-related CMS) (PMID: 26519543). - Single-fiber EMG (SFEMG): increased jitter and blocking — highly sensitive (~95% in CMS) (PMID: 33121830). LOINC / clinical neurophysiology. - Antibody testing: anti-AChR and anti-MuSK antibodies negative — essential to distinguish CMS18 from autoimmune myasthenia gravis. - Serum CK: typically normal. - Brain MRI: may show brain atrophy in the SNAP25-DEE spectrum (PMID: 33299146). - EEG: epileptiform abnormalities / cortical hyperexcitability.

Genetic testing (the definitive diagnostic modality). - Recommended approach: Because the phenotype overlaps both CMS and DEE, whole-exome sequencing (WES) or whole-genome sequencing (WGS) is the most effective route — this is how the index CMS18 variant was found (PMID: 25381298). Trio sequencing (proband + parents) confirms de novo status. - Gene panels: CMS and epileptic-encephalopathy NGS panels that include SNAP25 (alongside other SNARE genes STX1B, STXBP1, VAMP2). - Single-gene testing: SNAP25 Sanger confirmation of an identified variant. - CMA / karyotype / FISH / mtDNA / repeat testing: Not indicated — CMS18 is a point-mutation disorder.

Omics-based diagnostics. Not part of routine diagnosis; the I67N iPSC-neuron functional/proteomic work (PMID: 40181518) is a research characterization, not a clinical assay.

Clinical criteria & differential diagnosis. Diagnosis rests on (1) fatigable weakness with decremental RNS / abnormal SFEMG, (2) negative acetylcholine-receptor antibodies, and (3) a pathogenic SNAP25 variant. Differential diagnosis: autoimmune myasthenia gravis (antibody-positive, later onset), Lambert-Eaton myasthenic syndrome (presynaptic, VGCC antibodies, incremental response), other CMS subtypes (CHRNE, DOK7, RAPSN, SYT2, VAMP2), congenital myopathies, and mitochondrial disorders (CPEO). SFEMG jitter parameters help separate CMS from CPEO/congenital myopathy (PMID: 33121830).

Screening. No population newborn screening for CMS18. Given de novo dominant inheritance, carrier/cascade screening is generally not applicable (recurrence risk is low but non-zero due to possible germline mosaicism).

11. Outcome / Prognosis

Survival / mortality. No CMS18-specific survival data. CMS in general is not primarily lethal; life expectancy depends on severity of respiratory involvement (episodic apnea in some subtypes) and, for CMS18, on control of epilepsy and neurodevelopmental complications. Disease-specific mortality figures are unavailable given the rarity.

Morbidity / function. Substantial: combined motor weakness, intellectual disability, epilepsy, ataxia, and visual impairment produce long-term disability across mobility, cognition, and communication domains. Formal disability/QoL measures (ICF, EQ-5D, PROMIS) have not been applied to a CMS18 cohort.

Disease course / complications. Chronic lifelong. Complications include respiratory compromise during myasthenic exacerbations/infections, injury and developmental impact from refractory seizures, and secondary orthopedic issues (e.g., scoliosis seen broadly in chronic childhood NMJ disorders).

Recovery potential. No cure; the underlying synaptic defect is permanent. Symptomatic pharmacotherapy can meaningfully improve strength and function (see §12), and seizure control plus rehabilitation can improve developmental trajectory — but the neurodevelopmental deficits are generally not fully reversible.

Prognostic factors. Severity of the specific synaptic defect (variant-dependent), degree of epilepsy control, timeliness of correct genetic diagnosis (enabling genotype-appropriate therapy and avoidance of harmful agents), and access to specialized neuromuscular care.

12. Treatment

There is no cure. Management is symptomatic, genotype-guided, and multidisciplinary (Finding F005). The essential principle: CMS drug response is subtype-specific, and the wrong drug can worsen the patient.

"The majority of patients (96.4%) received specific treatment, including acetylcholinesterase inhibitors in 20, adrenergic agonists in 11 and 3,4-diaminopyridine in nine patients." — Austrian nationwide CMS cohort (PMID: 36308527)

"Treatment with acetylcholinesterase inhibitors resulted in worsened conditions for most patients." — DOK7-CMS meta-analysis (PMID: 24425145)

Rational pharmacotherapy for a presynaptic release defect (CMS18)

"Oral salbutamol and ephedrine appear to be effective treatments in severe cases of AChR deficiency on pyridostigmine ... improvement in strength can be dramatic." — PMID: 26296515

Advanced / experimental therapeutics. No approved gene, cell, or RNA therapy exists for CMS18. Given a dominant, likely dominant-negative de novo variant, allele-selective silencing (ASO/siRNA) is a conceptual future avenue but is not in trials. No CMS18-specific NCT trials are identified.

Supportive and rehabilitative care. Physical/occupational/speech therapy, respiratory support during exacerbations, nutritional support, seizure management, developmental/educational support, orthopedic monitoring (scoliosis). Pharmacogenomics: the key "pharmacogenomic" principle here is that the causal genotype (SNAP25 presynaptic release defect) dictates drug selection.

Treatment strategy (algorithm). Confirm genetic subtype → classify as presynaptic release defect → prioritize release-enhancing agents (3,4-DAP, β-agonists) → add AChE inhibitor only with caution and monitoring → manage epilepsy and provide multidisciplinary supportive care.

13. Prevention

• Primary prevention: None possible — de novo dominant variants cannot be prevented.
• Secondary prevention: Early recognition and correct genetic diagnosis enable prompt, subtype-appropriate therapy and avoidance of harmful drugs — the practical "prevention" of iatrogenic worsening and of complications.
• Tertiary prevention: Optimized pharmacotherapy, seizure control, respiratory vigilance during infections, and rehabilitation to prevent disability progression and complications.
• Immunization: Not disease-preventive, but standard vaccination is advisable to reduce infection-triggered myasthenic exacerbations (general principle).
• Genetic screening / counseling: Because most cases are de novo, recurrence risk to future siblings is low (residual risk from possible germline mosaicism). Genetic counseling should convey de novo status, low but non-zero recurrence risk, and the option of prenatal/preimplantation testing if a familial variant were established. NSGC/ACMG counseling frameworks apply.
• Public health / environmental interventions: Not applicable.

14. Other Species / Natural Disease

• Taxonomy / orthologs: SNAP25 is highly conserved across vertebrates and invertebrates. Human SNAP25 (NCBI Gene 6616) has orthologs including mouse Snap25 (NCBI Gene 20614) and rat Snap25; SNARE machinery is conserved to Drosophila and C. elegans (invertebrate SNARE studies inform mechanism — e.g., tomosyn regulation of SNARE assembly in C. elegans PMID: 17627987, and interchangeable VAMP function in Drosophila PMID: 12364587).
• Natural disease in other species: No well-characterized naturally occurring SNAP25-CMS is catalogued in companion animals or wildlife (OMIA does not list a prominent SNAP25 equivalent). Not applicable / not available.
• Comparative biology: The SNARE fusion mechanism is deeply evolutionarily conserved; disease mechanisms studied in model synapses translate directly to the human NMJ and central synapses. This conservation underpins the validity of animal and invertebrate models.
• Transmission / zoonosis: Not applicable (genetic, non-transmissible).

15. Model Organisms

• Human iPSC-derived neurons (primary CMS18 model): Østergaard et al. 2025 knocked the I67N variant into human iPSC-derived NGN2 glutamatergic neurons — the most disease-faithful available model — recapitulating reduced evoked and spontaneous release, decreased release probability, altered short-term plasticity, and proteome changes (PMID: 40181518). Recapitulation: high fidelity for the synaptic-release phenotype; limitation: does not model the intact NMJ, muscle, or whole-organism seizures/ataxia. Cellosaurus / iPSC.
• In vitro reconstitution & chromaffin cells: Shen et al. 2014 used liposome fusion assays and bovine chromaffin cell exocytosis to demonstrate causality (PMID: 25381298).
• Mouse (Snap25): Snap25-null mice reveal that SNAP-25 is essential for evoked release and network activity (PMID: 18959796, PMID: 17728451); isoform-rescue studies (SNAP-25a vs SNAP-25b vs SNAP-23) delineate functional specialization. A knock-in I67N mouse is a logical but (per available literature) not-yet-established disease model. MGI: Snap25.
• Invertebrate SNARE models: C. elegans and Drosophila SNARE/VAMP/tomosyn studies illuminate the conserved fusion machinery (PMID: 17627987, PMID: 12364587).
• Applications: These models enable study of release probability, evoked-vs-spontaneous release dissociation, short-term plasticity, and drug testing (e.g., release enhancers). Limitation: no single model captures the full combined myasthenic-plus-encephalopathic human phenotype.

Mechanistic Model / Interpretation

CMS18 is best understood as a "SNARE bottleneck" disorder: a single amino-acid change (Ile67→Asn) at the SN1 helix of SNAP-25 degrades the efficiency of the vesicle-fusion machine that every fast chemical synapse depends on. Because the same machine operates at the NMJ and at central synapses, a single molecular lesion produces a two-compartment disease — peripheral myasthenia plus central encephalopathy. This is the conceptual bridge between the "CMS18" and "SNAP25-DEE" labels for the same MONDO entity.

 SNAP25 p.I67N (de novo, dominant)
          │
  ┌───────────────┴───────────────┐
  ▼                               ▼
   PERIPHERAL (NMJ)                 CENTRAL (brain)
   ↓ ACh quantal release           ↓ glutamatergic/GABAergic release
   ↓ safety margin                 cortical hyperexcitability
   → fatigable weakness            → epilepsy, ataxia, ID
   (treatable: 3,4-DAP, β-agonist) (treat: antiseizure + supportive)

The variant-specific direction of effect on spontaneous release is the unifying explanatory axis for the whole SNAP25 spectrum: I67N reduces release (myasthenia-prone), while variants like V48F increase spontaneous release (encephalopathy without myasthenia). This makes SNAP25 a natural experiment in synaptic physiology and explains why the clinical picture ranges from CMS18-with-myasthenia to pure DEE.

Evidence Base

Limitations and Knowledge Gaps

1. Ultra-rarity → thin clinical evidence. CMS18 rests largely on a single index patient (Shen 2014) plus the broader ~23-individual SNAP25-DEE cohort. No CMS18-specific prevalence, survival, natural-history, or QoL data exist; epidemiology is borrowed from the CMS umbrella.
2. Treatment evidence is extrapolated. The recommended genotype-guided approach (3,4-DAP, β-agonists) is rational and grounded in presynaptic-CMS literature (SYT2, general reviews), but there is no dedicated CMS18 treatment trial. Direct evidence of drug response specifically in CMS18 patients is minimal (the iPSC drug-response work is a cell model).
3. Genotype–phenotype breadth. Whether other SNAP25 variants can produce a myasthenia-predominant CMS18 phenotype (vs pure DEE), and what determines the myasthenic vs encephalopathic balance, is only partially explained by the spontaneous-release-direction hypothesis.
4. No whole-animal I67N model is established to test therapies for the combined NMJ + CNS phenotype in vivo.
5. No CMS18-specific omics beyond the single iPSC proteome study; transcriptomic/metabolomic signatures are absent.
6. Recurrence-risk data (germline mosaicism) for SNAP25 are not quantified.

Proposed Follow-up Experiments / Actions

1. Build a knock-in I67N mouse (or refine iPSC-derived NMJ/organoid co-cultures) to model the combined myasthenic + encephalopathic phenotype and to test 3,4-DAP, β-agonists, and antiseizure combinations in vivo.
2. Systematic drug-response profiling in patient iPSC neurons — extend the Østergaard model to screen release-enhancers (3,4-DAP analogs, β-agonists) and candidate allele-selective ASOs for their ability to normalize release probability.
3. Establish an international CMS18/SNAP25 patient registry to aggregate phenotype, natural history, treatment response, and outcomes across the handful of cases worldwide — the only feasible route to real prevalence and prognosis estimates.
4. Genotype–function map of all reported SNAP25 variants correlating evoked-vs-spontaneous release direction with myasthenic vs encephalopathic clinical weighting, to build a predictive framework for prognosis and drug choice.
5. Prospective electrophysiology (RNS with post-exercise facilitation testing; SFEMG) in SNAP25 patients to confirm the presynaptic signature and define diagnostic criteria specific to CMS18.
6. Explore allele-selective silencing (ASO/siRNA) as a mechanism-directed therapy for this dominant, dominant-negative variant.

Report compiled from 6 confirmed findings across 5 investigation iterations and 37 reviewed papers. Ontology identifiers verified via EBI OLS4 (MONDO:0014590 → OMIM:616330). Gene identifiers: SNAP25, HGNC:11132, NCBI Gene 6616.

Artifacts

• OpenScientist final report
• OpenScientist final report